New England Peptide Opens Production Instrumentation Laboratory


Lab facilitates instrumentation R&D, qualification, maintenance

GARDNER, Mass., Dec. 12, 2007 – New England Peptide, LLC (NEP), has opened a new production instrumentation laboratory at its Massachusetts facility.

“The laboratory will allow NEP’s engineering team to bring the same level of focus and technology inherent in its R&D lab to new production technology,” says Sam Massoni, NEP’s founder and senior vice president of science and new technology.

“Customers turn to NEP for the highest-quality peptides available,” says Dave Robinson, CEO. “But what many people do not realize is that the company also is continuously developing industry leading production processes and technologies.”

NEP’s engineering team is no stranger to new technology development. In 2003, the group introduced a custom peptide array program. With the program, explains Robinson, customers are able to obtain NEP’s high-quality custom peptides in a 96-well plate format with a two-week leadtime – at $28 per peptide. “Our customers regularly remind us of how the peptide array program has changed the way they do research with peptides,” says Robinson. “They now have the time and financial resources to conduct research they previously could not afford.”

NEP’s engineering staff will use the dedicated lab to develop new instrumentation, qualify newly acquired production equipment, and efficiently bring instrumentation offline for maintenance.

New England Peptide (, founded in 1998, designs and produces custom peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. Headquartered in the Boston metro area in Gardner, Mass., the company’s chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications.

Peptides are small proteins that play key roles in biochemical regulation of all life systems, helping to fight diseases as diverse as cancer, diabetes, and HIV/AIDS. Peptides’ inherent low toxicity and high potency, coupled with improved drug delivery methods and enhanced manufacturing capabilities, are fueling a surge in use. All segments of the peptide market – from therapeutics and vaccines to diagnostics and cosmetics – are thriving.



"We have no reason to use any other antibody company at this point! We are very pleased with your work. We realize the difficulty in obtaining high quality phosphorylated antibodies so we desire to stick with NEP. Thank you for your work on this!"
Beth A. PhD - Florida State University